Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in
a concentration-dependent manner. This review describes the extensive clinical …

Although the incidence of venous thromboembolism (VTE) in Asian populations is lower
than in Western countries, the overall burden of VTE in Asia has been considerably …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Venous thromboembolism (VTE), manifesting as either deep vein thrombosis or pulmonary
embolism, is common worldwide including in Japan. The number of patients clinically …

Background Pharmacologic thromboprophylaxis (pTPX) might exacerbate the risk of
clinically relevant bleeding (CRB) and hospital-acquired anemia (HAA) in older multimorbid …

Particular concerns have been raised regarding the association between non‐vitamin K
antagonist oral anticoagulants (NOACs) and the risk of gastrointestinal bleeding (GIB); …

The direct thrombin inhibitor, dabigatran, as well as the direct factor Xa inhibtors
rivaroxaban, apixaban, and edoxaban, display pharmacodynamic features quite similar to …

Anticoagulants are amongst the most commonly prescribed medications worldwide.
Although rare, localised and systemic drug reactions have been reported with …

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly
used to prevent atrial fibrillation (AF) patients from thromboembolic events than vitamin K …

Venous thromboembolism (VTE) is a major cause of morbidity and mortality and is
associated with substantial healthcare costs. Identification of patients at risk of developing …